Anti-Human OX40L (Oxelumab) - APC Biosimilar (IVMB0438)
- SKU:
- IVMB0438
- Antibody Type:
- APC Biosimilar
- Modifications:
- APC-Conjugated
- Applications:
- IHC
- FC
- Drug Development
- Pharmacokinetics
- Disease Area:
- Cancer
Description
| Product Name: | Anti-Human OX40L (Oxelumab) - APC |
| SKU: | IVMB0438 |
| Size: | 50 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | R4930 |
| Target: | TNFSF4 |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | FA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B |
| Product Concentration: | 0.2 mg/ml |
| Excitation Laser: | Red Laser (650 nm) |
| Immunogen: | Original antibody raised against Human OX40L |
| Applications and Recommended Usage: | FC The suggested concentration for Oxelumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
| Antigen Distribution: | OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells. |
| Formulation: | This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product is for research use only. |
| Additional Applications Reported In Literature: | FA |
| Additional Reported Applications For Relevant Conjugates: | B |
Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
Anti-Human OX40L (Oxelumab) - PE Biosimilar (IVMB0439)
VivoGenie Anti-OX40L (Oxelumab) Biosimilar (IVMB0211)
Anti-Human OX40L (Oxelumab) - Dylight® 488 Biosimilar (IVMB0440)
VivoGenie Anti-OX40L (Oxelumab) Biosimilar (Fc Reduced) (IVMB0212)
